The significant EPS miss and declining gross margins are bearish signals. However, the affirmed guidance suggests management expects H2 2026 to be much stronger. Monitor Q2 2026 results for evidence of the promised recovery and any M&A announcements that could catalyze the stock.
KMDA drugs
KMDA drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $7.86entry
- T+1 · 6mo ago +2.16%α +1.39% · $8.03
- T+5 · 6mo ago −3.31%α −2.15% · $7.60
- T+20 · 5mo ago −5.34%α −4.73% · $7.44
- T+60 · 3mo ago −7.51%α −11.94% · $7.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kamada reported Q1 2026 EPS of $0.06, a 47.8% miss vs the $0.12 consensus, and revenue of $45.2M (+3% YoY) which was well below the $143.6M consensus (likely a mismatch in period, Q1 vs full-year). The company affirmed 2026 guidance of $200M-$205M revenue and $50M-$53M adjusted EBITDA, but the quarter was impacted by a temporary shipment delay. Net income was $4.1M, up 4% YoY.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of $0.06 missed consensus of $0.12 by 47.8%
- Q1 2026 revenue of $45.2M, up 3% YoY from $44.0M
- Gross margin declined to 42% from 47% YoY due to product/market mix
- Adjusted EBITDA of $11.6M, flat YoY
- Company affirms 2026 guidance: $200M-$205M revenue, $50M-$53M adjusted EBITDA
- Net income of $4.1M, up 4% YoY from $4.0M
- Cash and equivalents of $32.9M, down from $75.5M at year-end 2025
- FDA approval for San Antonio plasma collection center received in February 2026
Financial Impact
EPS miss of 47.8% vs consensus; revenue 68.5% below consensus (likely period mismatch); gross margin down 500 bps YoY
Risk Factors
- Continued gross margin compression from product mix shift
- Failure to deliver on H2 2026 guidance after Q1 miss
- Cash burn from plasma center investments and dividend payments
- Execution risk on M&A and business development initiatives
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293856 |
Track record
25 reports on KMDA
7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers